Vaccines are an especially risky proposition for pharmaceutical manufacturers since the costs are higher than for other types of drugs and demand could drop drastically once a crisis is over.
By
Compatibility issues still hinder implementations, but need is driving platforms forward.
By
A look at how platforms are changing heavy industry, finance, health care, and e-commerce.
By
Platforms are using data and preparing for Web3 and the metaverse, according to experts at the 2022 MIT Platform Summit.
By
A new study finds that artificial intelligence has been adopted unevenly in the U.S., with use clustered in large companies, industries such as manufacturing and health care, and certain cities.
By
MIT study explores the key factors behind patient outcomes in clinical trials evaluating new treatments for non-small-cell lung cancer.
By
The studies describe new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines.
By
MIT Sloan and CSAIL researchers apply artificial intelligence techniques to one of the largest datasets of clinical trial outcomes to handicap the drug and device approval process
By
The MIT Laboratory for Financial Engineering (LFE) and Informa Pharma Intelligence announced a new initiative, Project ALPHA (Analytics for Life-sciences Professionals and Healthcare Advocates).
Researchers launched an in-house Data Science and Artificial Intelligence (DSAI) challenge to beat MIT’s machine-learning models for predicting clinical trial outcomes. The results are now available.
